Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene

Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene

Author Tschope, C. Google Scholar
Walther, T. Google Scholar
Koniger, J. Google Scholar
Spillmann, F. Google Scholar
Westermann, D. Google Scholar
Escher, F. Google Scholar
Pauschinger, M. Google Scholar
Pesquero, J. B. Autor UNIFESP Google Scholar
Bader, M. Google Scholar
Schultheiss, H. P. Google Scholar
Noutsias, M. Google Scholar
Institution Free Univ Berlin
Universidade Federal de São Paulo (UNIFESP)
Max Delbruck Ctr Mol Med
Abstract Diabetic cardiomyopathy includes fibrosis. Kallikrein (KLK) can inhibit collagen synthesis and promote collagen breakdown. We investigated cardiac fibrosis and left ventricular (LV) function in transgenic rats (TGR) expressing the human kallikrein 1 (hKLK1) gene in streptozotocin (STZ) - induced diabetic conditions. Six weeks after STZ injection, LV function was determined in male Sprague-Dawley (SD) rats and TGR(hKLK1) (n = 10/group) by a Millar tip catheter. Total collagen content ( Sirius Red staining) and expression of types I, III, and VI collagen were quantified by digital image analysis. SD-STZ hearts demonstrated significantly higher total collagen amounts than normoglycemic controls, reflected by the concomitant increment of collagen types I, III, and VI. This correlated with a significant reduction of LV function vs. normoglycemic controls. in contrast, surface-specific content of the extracellular matrix, including collagen types I, III, and VI expression, was significantly lower in TGR( hKLK1)- STZ, not exceeding the content of SD and TGR( hKLK1) controls. This was paralleled by a preserved LV function in TGR( hKLK1)- STZ animals. the kallikrein inhibitor aprotinin and the bradykinin (BK) B2 receptor antagonist icatibant reduced the beneficial effects on LV function and collagen content in TGR( hKLK1)- STZ animals. Transgenic expression of hKLK1 counteracts the progression of LV contractile dysfunction and extracellular matrix remodeling in STZ-induced diabetic cardiomyopathy via a BK B2 receptor-dependent pathway.
Keywords diabetes mellitus
diabetic cardiomyopathy
kallikrein
pathogenesis
therapy
transgenic animal
Language English
Date 2004-05-01
Published in Faseb Journal. Bethesda: Federation Amer Soc Exp Biol, v. 18, n. 7, p. 828-835, 2004.
ISSN 0892-6638 (Sherpa/Romeo, impact factor)
Publisher Federation Amer Soc Exp Biol
Extent 828-835
Origin http://dx.doi.org/10.1096/fj.03-0736com
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000221883200031
URI http://repositorio.unifesp.br/handle/11600/27718

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account